Elucidating how mutations in EIF2AK4 cause pulmonary vascular disease

Pulmonary veno-occlusive disease (PVOD) is an incurable condition characterised by the progressive remodelling of pulmonary veins, venules and capillaries. This obstruction of the pulmonary vessels causes increased pulmonary pressures which leads to right ventricular hypertrophy, and death within 1-2 years if untreated. Biallelic mutations in the stress sensing kinase, EIF2AK4 (GCN2), are the main genetic cause of PVOD. I hypothesised that loss of GCN2 may lead to a pro-inflammatory phenotype which could be contributing to the development of PVOD. PVOD was modelled using mice with homozygous null mutations in *gcn2*. *Gcn2^-/-* mice spontaneously developed an increase in right ventricular systolic pressure, compared to wild-type controls (28.1 ± 3.4 vs. 24.7 ± 3.7 mmHg, p = 0.04). Both left and right ventricles exhibited hypertrophy in the *gcn2^-/-* mice but left ventricular systolic pressures were normal. Inflammatory cytokines, in particular interleukin 6, were raised in *gcn2^-/-* mice at baseline in both serum and lung compartments which was exaggerated after stimulation with LPS. Chronic exposure to LPS in *gcn2^-/-* mice led to elevated right ventricular systolic pressures which was prevented by genetic deletion of interleukin 6. Since the chemotherapy drug mitomycin-c can also induce PVOD in humans I decided to create an orthogonal model of PVOD by exposing wild-type mice to mitomycin-c. These mice also demonstrated right ventricular remodelling, which was prevented by genetic ablation of interleukin 6. Preliminary single-cell RNA sequencing analysis of lung cells from *gcn2^-/-* mice shows potential upregulation of pro-inflammatory pathways in *gcn2^-/-* macrophages and fibroblasts. I have shown, for the first time, that *gcn2^-/-* mice at baseline reproduce features of PVOD and share a pro-inflammatory phenotype with other forms of pulmonary hypertension and these are prevented by loss interleukin 6.

Name dc:type.qualificationname

Doctor of Philosophy (PhD)

Level dc:type.qualificationlevel

Doctoral

Grantor dc:publisher.institution

University of Cambridge

Year dc:date.issued

2024

Author dc:creator

• Schwiening, Max Henry

Advisors dc:contributor.advisor

• Marciniak, Stefan
• Soon, Elaine

• Cardiac
• EIF2AK4
• GCN2
• Mouse
• Pulmnonary arterial hypertension
• Pulmonary
• Pulmonary hypertension

Licence

• https://www.repository.cam.ac.uk/bitstreams/4db46f25-b05c-4780-95ce-4cdf0dfdbfe6/download
• http://purl.org/NET/rdflicense/allrightsreserved

Language dc:language

eng

DOI dc:identifier.doi

https://doi.org/10.17863/CAM.106526

OAI identifier oai:identifier

oai:www.repository.cam.ac.uk:1810/365109